Drugs / RNK08954
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07334262 | Dec 2025 → Dec 2026 expected | — | Ranok Therapeutics (Hangzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07441174 | Feb 2026 → Feb 2031 expected | pancreatic ductal adenocarcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06667544 | Nov 2024 → Dec 2026 expected | — | Ranok Therapeutics (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07303465 | Oct 2025 → Nov 2026 expected | pancreatic ductal adenocarcinoma | Ranok Therapeutics (Hangzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNK08954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06667544 ↗ |
| Action | Inhibit | “KRAS G12D inhibitor” NCT07334262 ↗ |
| Route | Oral | “Enrolled subjects will receive oral RNK08954 daily.” NCT06667544 ↗ |
| Target | KRAS | “KRAS G12D inhibitor” NCT07334262 ↗ |